For those of you who might be interested...
MALVERN, Pa. June 5, 2024 -- Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), today announced that it will host an investor webcast to discuss recent developments and future plans for its lead drug candidate, Buntanetap.
Investor Call Details:
Date and Time: June 11, 2024, 4:30pm ET.
Register Today:
zoom.us/webinar/register/WN...
Topics to Be Covered:
Recent advancements in the development of Buntanetap.
Strategic plans for upcoming clinical trials.
Overview of the company’s progress and future direction.
Register Today: Investors and interested parties are encouraged to register for the webcast in advance. To register, please visit zoom.us/webinar/register/WN... and complete the registration form.
About Buntanetap: Buntanetap (formerly known as Posiphen or ANVS401) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. By improving synaptic transmission, axonal transport, and reducing neuroinflammation, Buntanetap aims to reverse neurodegeneration in AD, PD, and other neurodegenerative diseases.
About Annovis Bio Inc.: Headquartered in Malvern, Pennsylvania, Annovis Bio Inc. is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit Annovis Bio's website and follow us on LinkedIn and X.
Annovis Bio have published the results of their dose-finding, biomarker study of buntanetap in 14 early Alzheimers & 14 Parkinsons patients
Good news from Annovis (for Alzheimer's)
